PTO FORM 1449

OIPE NOV - 9 1998 JC5 PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
52494/2101	**09/040,103**
APPLICANT **Mason**	RECEIVED
FILING DATE **March 17, 1998**	GROUP ~~1633~~ 1636

NOV 12 1998 TECHNOLOGY CENTER

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
R	4,405,712	9/20/83	Vande Woude et al.	435	5	7/1/81
R	5,562,904	10/8/96	Rother et al.	424	145.1	7/21/94
R	5,576,201	11/19/96	Mason et al.	435	456	1/14/94
R	5,580,766	12/3/96	Mason et al.	435	456	1/14/94
R	5,643,770	7/1/97	Mason et al.	435	456	7/21/94

*If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
R	WO89/07150	8/10/89	PCT				
R	WO92/07943	5/14/92	PCT				
R	EP 0178,220	4/16/86	EPO				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
R		Chong & Vile, "Replication-Competent Retrovirus Produced by a 'Split-function' Third Generation Amphotropic Packaging Cell Line", Gene Ther., 3:624-629, 1996
R		Cone & Mulligan, "High-efficiency Gene Transfer into Mammalian Cells: Generation of Helper-free Recombinant RetroVirus with Broad Mammalian Host Range", Proc. Nat'l. Acad. Sci. USA, 81:6349-6353, 1984
R		Cosset, et al., "High-titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum", J. Virol., 69:7430-7436, 1995
R		Crystal, "Transfer of Genes to Humans: Early Lessons and Obstracles to Success", Science, 270:404-410, 1995
R		Culver, et al., "In Vivo Gene Transfer with Retroviral Vector-producer Cells for Treatment of Experimental Brain Tumors", Science, 256:1550-1552, 1992
R		Eglitis, "Positive Selectable Markers for Use with Mammalian Cells in Culture", Hum. Gene Ther., 2:195-201, 1991
R		Eglitis & Anderson., "Retroviral Vectors for Introduction of Genes into Mammalian Cells", Biotechniques, 6:608-614, 1988
R		Galili, et al., "Evolutionary Relationship Between the Natural Anti-gal Antibody and the Galα-3gal Epitope in Primates", Proc. Nat'l. Acad. Sci. USA, 84:1369-1373, 1987
R		Gilboa, et al., "Transfer and Expression of Cloned Genes Using Retroviral Vectors", Biotechniques, 4:504-512, 1986
R		Girod, et al., "Homologous and Nonhomologous Retroviral Recombinations Are Both Involved in the Transfer by Infectious Particles of Defective Avian Leukosis Virus-derived Transcomplementing Genomes", J. Virol., 70:5651-5657, 1996

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Hoshino, et al., "Human T-cell Leukemia Virus Is Not Used by Human Serum", Nature, 310:324-325, 1984
		Mann, et al., "Construction of a Retrovirus Packaging Mutant and its Use to Produce Helper-free Defective Retrovirus", Cell, 33:153-159, 1983
		Martinez & Dornberg, "Partial Reconstitution of a Replication-competent RetroVirus in Helper Cells with Partial Overlaps Between Vector and Helper Cell Genomes", Hum. Gene Ther., 7:705-712, 1996
	14	Miller, "Human Gene Therapy Comes of Age", Nature, 357:455-460, 1992
		Miller & Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques, 7:980-990, 1989
		Morgenstern & Land, "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-free Packaging Cell Line", Nucleic Acds Res., 18:3587-3596, 1990
		Mulligan, "The Basic Science of Gene Therapy", Science, 260:926-932, 1993
	c	Neethling, et al., "Protection of Pig Kidney (Pk15) Cells from the Cytotoxic Effect of Anti-pig Antibodies by A-galactosyl Oligosaccharides", Transplant; 57:959-963, 1994
		Pensiero, et al., "Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human Serum", Hum. Gene Ther., 7:1095-1101, 1996
		Rem, et al., "Toxicity Studies of RetroViral-mediated Gene Transfer for the Treatment of Brain Tumors", J. Neurosurg., 79:400-407, 1993
		Rollins, et al., "Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response", Hum, Gene Ther., 7:619-626, 1996
		Rother, et al., "Protection of Retroviral Vector Particles in Human Blood Through Complement Inhibition," Hum. Gene Ther., 6:429-435, 1995
		Rother, et al., "A Novel Mechanism of Retrovirus Inactivation in Human Serum Mediated by Anti-α-galactosyl Natural Antibody," J. Exp. Med., 182:1345-1355, 1995
		Rother & Squinto., "The α-galactosyl Epitope: a Sugar Coating That Makes Viruses and Cells Unpalatable", Cell 86:185-188, 1996
		Russell, et al., "The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines", Hum. Gene Ther., 6:635-641, 1995
		Takeuchi, et al., "Sensitization of Cells and Retroviruses to Human Serum by (α1-3) Galactosyltransferase," Nature 379:85-88, 1996
		Takeuchi, et al., "Sensitization of Rhabdo-, Lenti-, and Spumaviruses to Human Serum by Galactosyl(α1-3) Galactosylation", J. Virol., 71:6174-6178, August 1997
		Takeuchi, et al., "Type C Retrovirus Inactivation by Human Complement Is Determined by Both the Viral Genome and the Producer Cell", J. Virol., 68:8001-8007, 1994
		Widner & Brundin, "Immunological Aspects of Grafting in the Mammalian Central Nervous System. A review and speculative synthesis", Brain Res. Rev., 13:287-324, 1988

EXAMINER	DATE CONSIDERED
David Yang	9/3/99

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.